Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients

被引:94
|
作者
Miyazaki, Y
Pipek, R
Mandarino, LJ
DeFronzo, RA
机构
[1] Univ Texas, Hlth Sci Ctr, Diabet Div, San Antonio, TX 78229 USA
[2] Texas Diabet Inst, San Antonio, TX USA
关键词
type; 2; diabetes; tumor necrosis factor alpha; insulin sensitivity;
D O I
10.1038/sj.ijo.0802187
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The relationship between basal serum tumor necrosis factor alpha (TNFalpha) levels and peripheral tissue (muscle) sensitivity to insulin was examined in 63 subjects with normal glucose tolerance (NGT), 18 subjects with impaired glucose tolerance (IGT), and 123 patients with type 2 diabetes mellitus (T2DM). The BMI was similar in NGT (28.8 +/- 0.7 kg/m(2)), IGT (31.1 +/- 1.0), and T2DM (30.0 +/- 0.4) groups. The fasting serum TNFalpha concentration in T2DM (4.4 +/- 0.2 pg/ml) was significantly higher than in NGT (3.1 +/- 0.2) and IGT (3.4 +/- 0.2; both P < 0.05). In T2DM the fasting plasma glucose (PPG 183 +/- 5 mg/dl) and insulin (FPI = 17 +/- 1 μU/ml) concentrations were significantly higher than in NGT (FPG = 95 +/- 1; FPI = 10 +/- 1) and IGT (FPG = 100 +/- 2; FPI = 13 +/- 1; all P < 0.01). The rate of total body insulin-mediated glucose disposal (Rd; 40 mU/m(2) min euglycemic insulin clamp in combination with H-3-glucose) was reduced in T2DM (102 +/- 3 mg/m(2) min) compared with NGT (177 10) and IGT (151 +/- 14; both P<0.01). The serum TNFα concentration was inversely correlated with Rd (r=-0.47, P<0.0001) and positively correlated with both FPG (r=0.32, P=0.004) and FPI (r=0.32, P=0.004) in NGT plus IGT. No correlation was observed between serum TNFalpha and Rd (r= -0.02), FPG (r= 0.15), or FPI (r= 0.15) in T2DM. In stepwise multiple regression analysis using age, sex, BMI, FPG, FPI and serum TNFalpha concentration as independent variables, only BMI and serum TNFalpha concentration were significant and independent predictors of Rd (r(2) = 0.29, P < 0.0001) in the NGT plus IGT group, while FPG and FPI were significant and independent predictors of Rd (r(2) = 0.13, P < 0.0001) in T2DM. These results suggest that: (i) an increase in circulating TNFalpha concentration is associated with peripheral insulin resistance and increased plasma glucose and insulin levels prior to the onset of type 2 diabetes; and (ii) the further deterioration in peripheral insulin resistance in T2DM (compared with NGT and IGT) is unrelated to the increase in serum TNFalpha concentration.
引用
收藏
页码:88 / 94
页数:7
相关论文
共 50 条
  • [1] Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients
    Y Miyazaki
    R Pipek
    L J Mandarino
    Ralph A DeFronzo
    International Journal of Obesity, 2003, 27 : 88 - 94
  • [2] Comparison of Tumor Necrosis Factor Alpha and Insulin Resistance in Observation Non-obese Type 2 Diabetic Patients
    Ijaz, Farhat
    Aftab, Rana Khurram
    Jawed, Samia
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2018, 24 (01): : 713 - 717
  • [3] Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients
    Ersoy, C
    Imamoglu, S
    Budak, F
    Tuncel, E
    Ertürk, E
    Oral, B
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2004, 120 (05) : 481 - 488
  • [4] Three measures of tumor necrosis factor a activity and insulin resistance in nonobese Japanese type 2 diabetic patients
    Ohya, M
    Taniguchi, A
    Fukushima, M
    Nakai, Y
    Kawasaki, Y
    Nagasaka, S
    Kuroe, A
    Taki, Y
    Yoshii, S
    Hosokawa, M
    Inagaki, N
    Seino, Y
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (10): : 1297 - 1301
  • [5] Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus
    Mishima, Y
    Kuyama, A
    Tada, A
    Takahashi, K
    Ishioka, T
    Kibata, M
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 52 (02) : 119 - 123
  • [6] Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients
    Paquot, N
    Scheen, AJ
    Dirlewanger, M
    Lefèbvre, PJ
    Tappy, L
    OBESITY RESEARCH, 2002, 10 (03): : 129 - 134
  • [7] The effect of sibutramine on insulin secretion and insulin resistance in obese Type 2 diabetic patients.
    Tankova, T
    Dakovska, G
    Lazarova, M
    Dakovska, L
    Kirilov, G
    Koev, D
    DIABETOLOGIA, 2003, 46 : A294 - A294
  • [8] Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α
    Giuseppe Derosa
    Arrigo F G Cicero
    Angela D'angelo
    Pietro D Ragonesi
    Leonardina Ciccarelli
    Mario N Piccinni
    Fabio Pricolo
    Sibilla A T Salvadeo
    Ilaria Ferrari
    Alessia Gravina
    Roberto Fogari
    Hypertension Research, 2006, 29 : 849 - 856
  • [9] Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone:: Effects on insulin-resistance, leptin and tumor necrosis factor-α
    Derosa, Giuseppe
    Cicero, Arrigo F. G.
    D'Angelo, Angela
    Ragonesi, Pietro D.
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Salvadeo, Sibilla A. T.
    Ferrari, Ilaria
    Gravina, Alessia
    Fogari, Roberto
    HYPERTENSION RESEARCH, 2006, 29 (11) : 849 - 856
  • [10] The significance of tumor necrosis factor-α in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment
    Chen, Haibing
    Ren, An
    Hu, Shilian
    Mo, Weilin
    Xin, Xuenong
    Jia, Weiping
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 75 (03) : 327 - 332